Japanese researchers report promising human trials for tooth-regrowing drug
Updated
Updated · NewsBytes · May 2
Japanese researchers report promising human trials for tooth-regrowing drug
8 articles · Updated · NewsBytes · May 2
At Kyoto University Hospital, adults aged 30 to 64 entered trials in late 2024, and by April 2026 the treatment had shown no major safety concerns.
The drug blocks the USAG-1 protein, reactivating dormant tooth buds so the body can grow new teeth instead of relying only on dentures or implants.
Researchers previously achieved tooth regrowth in mice and dogs and plan next to test children born without teeth, with possible clinical use targeted around 2030.
As human trials show promise, what are the hidden risks of reawakening our ability to grow teeth?
Could a single injection soon make dental implants and dentures a thing of the past?
From Orphan Drug to Market: TRG-035’s Journey to Regrow Teeth in Children and Adults
Overview
TRG-035 is a promising new drug that works by blocking the USAG-1 protein, which normally stops tooth growth after childhood. This action reactivates dormant tooth buds, allowing the body to naturally regrow complete, functional teeth with roots and supporting tissues. After successful animal studies showing safety and tooth regrowth, human Phase I trials began in 2024 to test safety and dosage in adults missing teeth. If these trials and planned Phase II studies in children with congenital tooth loss succeed, TRG-035 could become available by 2030. This breakthrough has the potential to transform dental care by offering a natural, long-lasting alternative to implants and dentures, possibly disrupting the $4.6 billion dental implant market.